p53, c-erbB-2 and nm23 expression have no prognostic significance in primary pulmonary adenocarcinoma

Mackinnon, Murray; Km, Kerr; King, G.; Mm, Kennedy; Js, Cockburn; Rr, Jeffrey

doi:10.1016/s1010-7940(97)01162-7

Cited by 22 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One article examined samples from lymph node metastases. Accordingly, 24 articles that described 19 studies5, 12–34 were excluded from the current metaanalysis (Table 1), whereas 20 articles7, 8, 35–52 fulfilled the eligibility criteria (Table 2).…”

Section: Methodsmentioning

confidence: 99%

Association of HER‐2 overexpression with prognosis in nonsmall cell lung carcinoma: A metaanalysis

Nakamura

Kawasaki

Taguchi

et al. 2005

Cancer

View full text Add to dashboard Cite

BACKGROUNDPrognostic implications of overexpression of the HER‐2 gene in nonsmall cell lung carcinoma (NSCLC) are a matter of controversy. Many conflicting results have been reported from different laboratories.METHODSA metaanalysis of published studies was performed for this quantitative review of the effects of HER‐2 overexpression on survival among patients with NSCLC. Of 44 articles initially selected, 20 articles fulfilled eligibility criteria. DerSimonian–Laird random effects analysis was used to estimate the effects of HER‐2 overexpression on survival differences (the survival rate among patients without HER‐2 overexpression minus the survival rate among patients with HER‐2 overexpression) at endpoints of 1 years, 3 years, and 5 years after resection of NSCLC.RESULTSIn total, 2579 patients were included in the final analysis. Overall, HER‐2 positivity differed according to histologic type and included 38% of patients with adenocarcinoma, 16% of patients with squamous cell carcinoma, and 18% of patients with large cell carcinoma (P < 0.0001). The combined survival differences in patients with NSCLC at 1 year, 3 years, and 5 years, respectively, were 2.7% (95% confidence interval [95% CI], 1.3–6.7%; P = 0.1787), 15.2% (95% CI, 5.8–24.5%; P = 0.0015), and 16.4% (95% CI, 7.9–14.8%; P = 0.0001), suggesting significant poorer survival at 3 years and 5 years among patients with HER‐2 overexpression. In patients with adenocarcinoma, the combined survival difference at 5 years was 26.0% (95% CI, 16.0–36.1%; P < 0.0001), suggesting a particularly strong survival impact for HER‐2 overexpression.CONCLUSIONSA significant, unfavorable prognostic effect of HER‐2 overexpression in NSCLC was evident from the metaanalysis. However, because several studies that found no significant difference were excluded by the current eligibility criteria, caution is needed in interpreting the results. Cancer 2005. © 2005 American Cancer Society.

show abstract

Section: Methodsmentioning

confidence: 99%

Association of HER‐2 overexpression with prognosis in nonsmall cell lung carcinoma: A metaanalysis

Nakamura

Kawasaki

Taguchi

et al. 2005

Cancer

View full text Add to dashboard Cite

show abstract

“…The reasons for noninclusion of a study into the meta-analysis were: absence of univariate analysis (n=3) [37,63,80]; no p-value, HR or CI reported (n=8) [11,23,24,49,61,62,67,91]; no survival curve shown (n=5) [17,31,35,53,81]; no p53 status distribution (n=2) [28,73].…”

Section: Study Selection and Characteristicsmentioning

confidence: 99%

Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis

et al. 2001

View full text Add to dashboard Cite

The role of p53, as a prognostic factor for survival in lung cancer, is controversial and the purpose of the present systematic review of the literature is to determine this effect.Published studies were identified with the objective to aggregate the available survival results after a methodological assessment using a scale specifically designed by the European Lung Cancer Working Party (ELCWP). To be eligible, a study had to deal with p53 assessment in lung cancer (primary site) only, and to provide a survival comparison according to the p53 status.Among the 74 eligible papers, 30 identified p53 abnormalities as a univariate statistically significant poor prognostic factor and 56 provided sufficient data to allow survival results aggregation. There was no significant difference between the trials that either showed or did not show a prognostic effect of p53 according to the methodological score or to the laboratory technique used. The studies were categorized by histology, disease stage, treatment and laboratory technique. Combined hazard ratios suggested that an abnormal p53 status had an unfavourable impact on survival: in any stage nonsmall cell lung cancer (NSCLC) the mean (95% confidence interval) was 1.44 (1.20-1.72) (number of studies included in the subgroup was 11), 1.50 (1.32-1.70) in stages I-II NSCLC (n=19), 1.68 (1.23-2.29) in stages I-IIIB NSCLC (n=5), 1.68 (1.30-2.18) in stages III-IV NSCLC (n=9), 1.48 (1.29-1.70) in surgically resected NSCLC (n=20), 1.37 (1.02-1.85) in squamous cell carcinoma (n=9), 2.24 (1.70-2.95) in adenocarcinoma (n=9), 1.57 (1.28-1.91) for a positive immunohistochemistry with antibody 1801 (n=8), 1.25 (1.09-1.43) for a positive immunohistochemistry with antibody DO-7 (n=16), and 1.65 (1.35-2.00) for an abnormal molecular biology test (n=13). Data were insufficient to determine the prognostic value of p53 in small cell lung cancer.In each subgroup of nonsmall cell lung cancer, p53 abnormal status was shown to be associated with a poorer survival prognosis. Lung cancer is the most common cause of cancer death in industrialized countries and its incidence is steadily increasing in females and in many European countries. Despite improvements in diagnosis and therapy, the overall 5-yr survival is still 15%.Some independent prognostic factors have been identified for predicting survival and helping in the management of patients with lung cancer [1]. They include: for small cell lung cancer (SCLC), extent of disease and performance status (PS) [2]; for resectable nonsmall cell lung cancer (NSCLC), PS, tumour, node, metastasis (TNM) stage, and age [3]; for advanced NSCLC, PS, TNM stage, age, sex and weight loss [4,5]. Among biological factors, white blood cell count, serum lactate dehydrogenase level, angiogenesis and factors reflecting proliferative state have been shown to significantly predict outcome [6,7].Recent progresses in molecular biology have allowed for the extension of the research on prognostic factors to the analysis of proteins and genes involved in cancer...

show abstract

“…A total of 39 studies, published between 1990 and 2002, were found eligible (Kern et al, 1990(Kern et al, , 1994Tateishi et al, 1991Tateishi et al, , 1994Volm et al, 1992Volm et al, , 1993aHarpole et al, 1995aHarpole et al, , b, 1996Giatromanolaki et al, 1996a, b;Pfeiffer et al, 1996;Koukouraki et al, 1997Koukouraki et al, , 2000MacKinnon et al, 1997;Pastorino et al, 1997;Visscher et al, 1997;Yu et al, 1997;Graziano et al, 1998;Greatens et al, 1998;Hsieh et al, 1998;Kim et al, 1998;Kwiatkowski et al, 1998;Nemunaitis et al, 1998;Cantero et al, 1999Cantero et al, , 2000D'Amico et al, 1999;Fu et al, 1999;Moldvay et al, 2000;Schneider et al, 2000;Ardizzoni et al, 2001;Brabender et al, 2001;Liao et al, 2001;Shou et al, 2001;Carbognani et al, 2002;Han et al, 2002;Hirsch et al, 2002;Potti et al, 2002;Selvaggi et al, 2002). Nine of the articles were excluded because identical cohorts of patients were used (studies that were excluded and included were, respectively, references (Cantero et al, 1999) and (Cantero et al, 2000), (Giatromanolaki et al, 1996b;…”

Section: Studies Selection and Characteristicsmentioning

confidence: 99%

The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature

et al. 2003

View full text Add to dashboard Cite

C-erbB-2 prognostic value for survival in patients with lung cancer remains controversial. We performed a systematic review of the literature to clarify its impact. Studies were identified by an electronic search in order to aggregate the survival results, after a methodological assessment using the scale of the European Lung Cancer Working Party. To be eligible, a study had to deal with cerbB-2 assessment in lung cancer patients and to analyse survival according to c-erbB-2 expression. In total, 30 studies were eligible: 24 studies dealt with non-small-cell lung carcinoma (NSCLC), five with adenocarcinoma and one study dealt with small-cell carcinoma. In all, 31% of the patients were positive for c-erbB-2. According to c-erbB-2 expression, 13 studies were 'negative' (significant detrimental effect on survival), one 'positive' (significant survival improvement) and 16 not significant. Significant studies had a better subscore relative to analysis and results report than nonsignificant studies. In total, 86% of the significant studies and only 56% of the nonsignificant studies were evaluable for the meta-analysis. This suggests a possible bias in our aggregated results. For NSCLC, the hazard ratio was 1.55 (95% CI: 1.29 -1.86) in favour of tumours that do not express c-erbB-2. In conclusion, the overexpression of c-erbB-2 might be a factor of poor prognosis for survival in NSCLC, but there is a potential bias in favour of the significant studies with an overestimation risk of the magnitude of the true effect of c-erbB-2 overexpression.

show abstract

p53, c-erbB-2 and nm23 expression have no prognostic significance in primary pulmonary adenocarcinoma

Abstract: Immunohistochemical assessment of the nm23, c-erbB-2 and p53 proteins using the above monoclonal antibodies does not have value as an independent prognostic indicator in pulmonary adenocarcinoma.

Cited by 22 publications

References 0 publications

Association of HER‐2 overexpression with prognosis in nonsmall cell lung carcinoma: A metaanalysis

Association of HER‐2 overexpression with prognosis in nonsmall cell lung carcinoma: A metaanalysis

Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis

The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature

Contact Info

Product

Resources

About